Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.46 |
| ▸ | TYMS | P04818 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22984016 | 1.00 | TYMP (0.46) | TYMPTYMSPOLBTMIGD3ADORA3 | |
| SCHEMBL21828786 | 1.00 | TYMP (0.46) | TYMPTYMSPOLBTMIGD3ADORA3 | |
| SCHEMBL21504687 | 0.92 | POLB (0.40) | TYMPPOLBTMIGD3ADORA3ADORA1 | |
| SCHEMBL3510681 | 0.89 | TYMP (0.43) | TYMPTYMSPOLBTMIGD3ADORA3 | |
| SCHEMBL3510678 | 0.89 | TYMP (0.43) | TYMPTYMSPOLBTMIGD3ADORA3 | |
| SCHEMBL22983996 | 0.89 | POLB (0.40) | TYMPPOLBTMIGD3ADORA3ADORA1 | |
| SCHEMBL6274851 | 0.88 | TYMP (0.39) | TYMPPOLB | |
| SCHEMBL7069679 | 0.88 | TYMP (0.42) | TYMPTYMSPOLBTMIGD3ADORA3 | |
| SCHEMBL7069682 | 0.88 | TYMP (0.42) | TYMPTYMSPOLBTMIGD3ADORA3 | |
| SCHEMBL21473350 | 0.87 | ABL1 (0.47) | TYMPTMIGD3ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 586 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4741411-A2 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-12269841-B2 | Production method for oligonucleotides | AJINOMOTO CO., INC. (JP) | 2025-04-08 | — | — | US | disclosed |
| CN-113631564-B | Method for producing oligonucleotide having phosphorothioate site | 味之素株式会社 | 2025-02-25 | — | — | CN | disclosed |
| CN-119431453-A | Phosphorus (V) based reagent, method for the production thereof, and use thereof for producing stereoregular organic phosphorus (V) compounds | 百时美施贵宝公司 | 2025-02-14 | — | — | CN | disclosed |
| CN-112236438-B | Phosphorus (V) based reagent, method for the production thereof, and use thereof for producing stereoregular organic phosphorus (V) compounds | 百时美施贵宝公司 | 2024-10-15 | — | — | CN | disclosed |
| US-12077558-B2 | Phosphorus (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophosphorus (V) compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-03 | — | — | US | disclosed |
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2024-01-18 | — | — | US | disclosed |
| US-11859186-B2 | Antisense oligonucleotides useful in treatment of Pompe disease | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2024-01-02 | — | — | US | disclosed |
| EP-4293035-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | AJINOMOTO CO., INC. (JP) | 2023-12-20 | — | — | EP | disclosed |
| CN-116888136-A | Method for preparing oligonucleotides | 味之素株式会社 | 2023-10-13 | — | — | CN | disclosed |
| US-20030225256-A1 | Antisense modulation of pctaire protein kinase 2 expression | ISIS PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030225015-A1 | Antisense modulation of Rb2/p130 expression | ISIS PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030225019-A1 | Notch1 inhibitors for inducing apoptosis | ISIS PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003100017-A2 | OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030224517-A1 | Antisense modulation of beta-site APP-cleaving enzyme 2 expression | ISIS PHARMACEUTICALS INC. | 2003-12-04 | — | — | US | disclosed |
| US-20030219895-A1 | An oligonucleotide or a hybrids for encoding a protein kinase | ISIS PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030220273-A1 | Antisense modulation of phosphodiesterase 4D expression | ISIS PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | disclosed |
| US-20030212017-A1 | Antisense modulation of farnesyl transferase beta subunit expression | ISIS PHARMACEUTICALS INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030211606-A1 | Antisense modulation of DYRK4 expression | ISIS PHARMACEUTICALS INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030198965-A1 | Antisense modulation of hydroxysteroid 11-beta dehydrogenase 1 expression | ISIS PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077558-B2 | Phosphorus (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophosphorus (V) compounds | PPIP5K2, PLCB3, PLCG2 | TYMP 96/4885TYMS 1028/4885POLB 1063/4885 |
| US-20240018180-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, NOX4, POLRMT | TYMP 101/4885TYMS 239/4885POLB 30/4885 |
| US-12269841-B2 | Production method for oligonucleotides | RNGTT, DCLRE1B, PHOSPHO1 | TYMP 30/4885TYMS 98/4885POLB 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.